Galmed Pharmaceuticals Ltd (GLMD) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 9 from a previous price target of $24 . Maxim Group advised their investors in a research report released on Aug 1, 2016.
Many Wall Street Analysts have commented on Galmed Pharmaceuticals Ltd. ROTH Capital Resumed Galmed Pharmaceuticals Ltd on Jul 6, 2016 to “Buy”, Price Target of the shares are set at $6.
Galmed Pharmaceuticals Ltd opened for trading at $4.15 and hit $4.5 on the upside on Friday, eventually ending the session at $4.27, with a gain of 2.89% or 0.12 points. The heightened volatility saw the trading volume jump to 74,407 shares. Company has a market cap of $47 M.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate or FABAC called aramchol. Its product candidate aramchol has the potential to be a disease modifying treatment for fatty liver disorders including Non-Alcoholic Steato-hepatitis (NASH) which constitutes an unmet medical need. The Company has completed three clinical trials of aramchol. The Company focuses on providing a multi-center double-blind randomized Phase IIb placebo-controlled clinical trial of aramchol in NASH patients who also suffer from obesity and insulin resistance. The Company is engaged in developing aramchol for the treatment of NASH in patients who also suffer from obesity and insulin resistance.